5-bromo-2-(methoxymethoxy)benzonitrile | 1033602-66-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-bromo-2-(methoxymethoxy)benzonitrile
• 英文别名: 5-bromo-2-methoxymethoxylbenzonitrile；5-bromo-2-methoxy-methoxybenzonitrile
• CAS: 1033602-66-2
• 化学式: C₉H₈BrNO₂
• mdl: MFCD12913647
• 分子量: 242.072
• InChiKey: WVKSARNSMSRZSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-2-(methoxymethoxy)benzonitrile 在 palladium diacetate 、 三(邻甲基苯基)磷 盐酸 、 正丁基锂 、 硼酸三异丙酯 、 sodium carbonate 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙二醇二甲醚 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 ethyl 2-[4-(3-chloropropoxy)-3-cyanophenyl]nicotinate
  参考文献：
  名称：

  EP2128136

  摘要：

  公开号：
• 作为产物：
  描述：

  5-溴水杨醛 在 甲酸 、 盐酸羟胺 、 potassium tert-butylate 、 sodium formate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 5-bromo-2-(methoxymethoxy)benzonitrile
  参考文献：
  名称：

  EP2128136

  摘要：

  公开号：

文献信息

• 2-PHENYLNICOTINIC ACID DERIVATIVE
  申请人：Menjo Nobuo

  公开号：US20100004459A1

  公开（公告）日：2010-01-07

  The present invention is to provide the compounds useful as a treating or preventing agent for gout and hyperuricemia which are 2-phenylnicotinic acid derivatives having a uric acid lowering action due to an excellent xanthine oxidase inhibitory action. Since the 2-phenylnicotinic acid derivatives of the present invention exhibit a uric acid lowering action due to an excellent xanthine oxidase inhibitory action and also hypolipemic action, their utility is very high as a treating or preventive agent for gout and hyperuricemia which are often accompanied by hyperlipemia as a complication.

  本发明提供了一种化合物，它是2-苯基烟酸衍生物，具有出色的黄嘌呤氧化酶抑制作用，可用作痛风和高尿酸血症的治疗或预防剂。由于本发明的2-苯基烟酸衍生物表现出出色的黄嘌呤氧化酶抑制作用和降脂作用，因此它们作为治疗或预防痛风和高尿酸血症的药物，其实用价值非常高，因为这些疾病通常伴随着高脂血症的并发症。
• Structure−Activity Relationships Comparing <i>N</i>-(6-Methylpyridin-yl)-Substituted Aryl Amides to 2-Methyl-6-(substituted-arylethynyl)pyridines or 2-Methyl-4-(substituted-arylethynyl)thiazoles as Novel Metabotropic Glutamate Receptor Subtype 5 Antagonists
  作者：Santosh S. Kulkarni、Mu-Fa Zou、Jianjing Cao、Jeffrey R. Deschamps、Alice L. Rodriguez、P. Jeffrey Conn、Amy Hauck Newman

  DOI：10.1021/jm900172f

  日期：2009.6.11

  The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in anxiety, depression, pain, mental retardation, and addiction. The potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP, 1) has been a critically important tool used to further elucidate the role of mGluR5 in these CNS disorders. In an effort to provide novel and structurally diverse selective mGluR5 antagonists, we previously described a set of analogues with moderate activity wherein the alkyne bond was replaced with an amide group. In the present report, extended series of both amide and alkyne-based ligands were synthesized. MGluR5 binding and functional data were obtained that identified (1) several novel alkynes with comparable affinities to 1 at mGluR5 (e.g., 10 and 20-23), but (2) most structural variations to the amide template were not well tolerated, although a few potent amides were discovered (e.g., 55 and 56). Several of these novel analogues show drug-like physical properties (e.g., cLogP range = 2-5) that support their use for in vivo investigation into the role of mGluR5 in CNS disorders.
• Structure–activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5
  作者：Peng Zhang、Mu-Fa Zou、Alice L. Rodriguez、P. Jeffrey Conn、Amy Hauck Newman

  DOI：10.1016/j.bmc.2010.03.053

  日期：2010.5

  The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in numerous neuropsychiatric disorders including addiction. We have discovered that the rigid diaryl alkyne template, derived from the potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl) pyridine (MPEP), can serve to guide the design of novel quinoline analogues and pharmacophore optimization has resulted in potent mGluR5 noncompetitive antagonists (EC(50) range 60-100 nM) in the quinoline series. Published by Elsevier Ltd.